Skip to main content

 Related scientific articles (all)

Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.

Authors : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Authors : Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M
Year : 2022
Journal : Expert Opin Investig Drugs
Volume : 31
Pages : 567-591

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Authors : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Year : 2022
Journal : Diagnostics (Basel)
Volume : 12

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Authors : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Year : 2022
Journal : Eur J Cancer
Volume : 168
Pages : 138-140

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.

Authors : Garaud S, Dieu-Nosjean MC, Willard-Gallo K
Year : 2022
Journal : Nat Commun
Volume : 13
Pages : 2259

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

Authors : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R
Year : 2022
Journal : Virchows Arch
Volume : 480
Pages : 147-162

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Authors : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Year : 2022
Journal : Eur J Cancer
Volume : 166
Pages : 219-228

Downregulation of the FTO m<sup>6</sup>A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.

Authors : Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F
Year : 2021
Journal : Nat Cancer
Volume : 2
Pages : 611-628

Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.

Authors : Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S
Year : 2021
Journal : Acta Clin Belg
Volume : 76
Pages : 144-148

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Authors : El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 150

Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity.

Authors : Noël G, Fontsa ML, Garaud S, De Silva P, de Wind A, Van den Eynden GG, Salgado R, Boisson A, Locy H, Thomas N, Solinas C, Migliori E, Naveaux C, Duvillier H, Lucas S, Craciun L, Thielemans K, Larsimont D, Willard-Gallo K
Year : 2021
Journal : J Clin Invest
Volume : 131

Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?

Authors : De Silva P, Aiello M, Gu-Trantien C, Migliori E, Willard-Gallo K, Solinas C
Year : 2021
Journal : Int J Cancer
Volume : 149
Pages : 31-41

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.

Authors : van de Stolpe A, Verhaegh W, Blay JY, Ma CX, Pauwels P, Pegram M, Prenen H, De Ruysscher D, Saba NF, Slovin SF, Willard-Gallo K, Husain H
Year : 2021
Journal : Front Genet
Volume : 11
Pages : 598118

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

Authors : Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S
Year : 2021
Journal : J Natl Cancer Inst
Volume : 114(3)
Pages : 467-70

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.

Authors : Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C
Year : 2021
Journal : Mol Diagn Ther
Volume : 25
Pages : 409-424

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.

Authors : Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, Pipy B, Jeannin P, Prost JF, Barret JM, Coste A
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

Authors : Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein AM, Francis PA, Di Leo A, Viale G, de Azambuja E, Ameye L, Sotiriou C, Salmon A, Kravchenko-Balasha N, Sonnenblick A
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 67

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Authors : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Year : 2021
Journal : BMC Cancer
Volume : 21
Pages : 899

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis.

Authors : Caparica R, Bruzzone M, Agostinetto E, Franzoi MA, Ceppi M, Radosevic-Robin N, Penault-Llorca F, Willard-Gallo K, Loi S, Salgado R, de Azambuja E
Year : 2021
Journal : Breast
Volume : 59
Pages : 183-192